MX2019003103A - Composicion farmaceutica. - Google Patents
Composicion farmaceutica.Info
- Publication number
- MX2019003103A MX2019003103A MX2019003103A MX2019003103A MX2019003103A MX 2019003103 A MX2019003103 A MX 2019003103A MX 2019003103 A MX2019003103 A MX 2019003103A MX 2019003103 A MX2019003103 A MX 2019003103A MX 2019003103 A MX2019003103 A MX 2019003103A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- beclomethasone
- component
- hfa
- difluoroethane
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- 229940092705 beclomethasone Drugs 0.000 abstract 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 abstract 1
- 229940051271 1,1-difluoroethane Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- -1 beclomethasone compound Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se describe una composición farmacéutica. La composición comprende: (i) un componente de fármaco que comprende al menos un compuesto de beclometasona seleccionado de beclometasona y los derivados aceptables desde el punto de vista farmacéutico de esta y al menos un beta-2-agonista de acción prolongada; (ii) un componente propulsor que comprende 1,1-difluoroetano (HFA-152a); y (iii) glicerol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1615908.9A GB2554088A (en) | 2016-09-19 | 2016-09-19 | Pharmaceautical composition |
| GBGB1620515.5A GB201620515D0 (en) | 2016-12-02 | 2016-12-02 | Pharmaceutical composition |
| PCT/GB2017/052762 WO2018051131A1 (en) | 2016-09-19 | 2017-09-18 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003103A true MX2019003103A (es) | 2019-08-01 |
Family
ID=59997387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003103A MX2019003103A (es) | 2016-09-19 | 2017-09-18 | Composicion farmaceutica. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190388436A1 (es) |
| EP (3) | EP3610877A1 (es) |
| JP (2) | JP6781832B2 (es) |
| KR (1) | KR102279445B1 (es) |
| CN (3) | CN113069417A (es) |
| AU (2) | AU2017328908B2 (es) |
| BR (1) | BR112019005113A2 (es) |
| CA (1) | CA3037257C (es) |
| CO (1) | CO2019002555A2 (es) |
| EA (1) | EA201990501A1 (es) |
| ES (1) | ES2841649T5 (es) |
| GE (1) | GEP20217240B (es) |
| IL (1) | IL265349B2 (es) |
| MX (1) | MX2019003103A (es) |
| MY (1) | MY202030A (es) |
| PE (1) | PE20191044A1 (es) |
| PH (1) | PH12019500577A1 (es) |
| UA (1) | UA124240C2 (es) |
| WO (1) | WO2018051131A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252552A (zh) * | 2016-09-19 | 2022-11-01 | 墨西哥氟石股份公司 | 药物组合物 |
| WO2020152548A1 (en) * | 2019-01-24 | 2020-07-30 | Glenmark Pharmaceuticals Limited | Stable aerosol inhalation compositions of formoterol |
| GB2584686A (en) * | 2019-06-11 | 2020-12-16 | Mexichem Fluor Sa De Cv | Methods |
| GB2586477A (en) * | 2019-08-20 | 2021-02-24 | Mexichem Fluor Sa De Cv | Composition and method |
| IL293328A (en) | 2019-12-02 | 2022-07-01 | Chiesi Farm Spa | Stainless steel canister for pressurized metered dose inhalers |
| JP2023511615A (ja) * | 2020-01-28 | 2023-03-20 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 緩衝化医薬製剤を含む加圧定量吸入器 |
| MX2022009643A (es) * | 2020-02-20 | 2022-09-07 | Chiesi Farm Spa | Inhaladores dosificadores presurizados que comprenden una formulacion farmaceutica amortiguada. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2326334A (en) * | 1997-06-13 | 1998-12-23 | Chiesi Farma Spa | Pharmaceutical aerosol compositions |
| DE69813853T3 (de) | 1997-09-29 | 2011-05-12 | Novartis Ag | Perforierte mikroteilchen und deren verwendung |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| EP1575588A1 (en) * | 2002-12-16 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Tiotropium containing hfc solution formulations |
| EP1982709A1 (en) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma |
| US10179139B2 (en) * | 2010-10-12 | 2019-01-15 | Cipla Limited | Pharmaceutical composition |
| RU2013142268A (ru) * | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| GB201108039D0 (en) * | 2011-05-13 | 2011-06-29 | Mexichem Amanco Holding Sa | Compositions |
| GB201117619D0 (en) * | 2011-10-12 | 2011-11-23 | Mexichem Amanco Holding Sa | Compositions |
| CN104918604A (zh) * | 2012-10-23 | 2015-09-16 | 西普拉有限公司 | 药物组合物 |
| GB201306984D0 (en) | 2013-04-17 | 2013-05-29 | Mexichem Amanco Holding Sa | Composition |
| WO2017093758A1 (en) | 2015-12-04 | 2017-06-08 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| AU2017328907B2 (en) * | 2016-09-19 | 2020-04-09 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN115252552A (zh) * | 2016-09-19 | 2022-11-01 | 墨西哥氟石股份公司 | 药物组合物 |
-
2017
- 2017-09-18 AU AU2017328908A patent/AU2017328908B2/en active Active
- 2017-09-18 IL IL265349A patent/IL265349B2/en unknown
- 2017-09-18 ES ES17777636T patent/ES2841649T5/es active Active
- 2017-09-18 CN CN202110273940.8A patent/CN113069417A/zh active Pending
- 2017-09-18 JP JP2019515271A patent/JP6781832B2/ja active Active
- 2017-09-18 WO PCT/GB2017/052762 patent/WO2018051131A1/en active Application Filing
- 2017-09-18 US US16/334,156 patent/US20190388436A1/en active Pending
- 2017-09-18 MY MYPI2019001314A patent/MY202030A/en unknown
- 2017-09-18 PE PE2019000675A patent/PE20191044A1/es unknown
- 2017-09-18 CN CN201780057285.4A patent/CN109789151A/zh active Pending
- 2017-09-18 EP EP19199776.6A patent/EP3610877A1/en active Pending
- 2017-09-18 EP EP19199786.5A patent/EP3607951A1/en active Pending
- 2017-09-18 EP EP17777636.6A patent/EP3515451B2/en active Active
- 2017-09-18 CA CA3037257A patent/CA3037257C/en active Active
- 2017-09-18 EA EA201990501A patent/EA201990501A1/ru unknown
- 2017-09-18 CN CN202310774818.8A patent/CN116898804A/zh active Pending
- 2017-09-18 UA UAA201902773A patent/UA124240C2/uk unknown
- 2017-09-18 KR KR1020197010383A patent/KR102279445B1/ko active IP Right Grant
- 2017-09-18 GE GEAP201715034A patent/GEP20217240B/en unknown
- 2017-09-18 BR BR112019005113A patent/BR112019005113A2/pt active Search and Examination
- 2017-09-18 MX MX2019003103A patent/MX2019003103A/es unknown
-
2019
- 2019-03-18 PH PH12019500577A patent/PH12019500577A1/en unknown
- 2019-03-19 CO CONC2019/0002555A patent/CO2019002555A2/es unknown
- 2019-09-25 US US16/582,710 patent/US20200016174A1/en active Pending
- 2019-09-25 US US16/582,964 patent/US20200016175A1/en active Pending
-
2020
- 2020-03-11 JP JP2020042092A patent/JP6980050B2/ja active Active
- 2020-04-20 AU AU2020202651A patent/AU2020202651C1/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500577A1 (en) | Pharmaceutical composition | |
| PH12019500579A1 (en) | Pharmaceutical composition | |
| MX2019003099A (es) | Composicion farmaceutica. | |
| MX2019003097A (es) | Composicion farmaceutica. | |
| MX2018006800A (es) | Composicion farmaceutica. | |
| GEP20237470B (en) | Magl inhibitors | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| PH12019502676A1 (en) | Moisturizing topical preparation | |
| PH12020550125A1 (en) | Crystalline forms of 3-substituted 1,2,4-oxadiazole | |
| MX2021010022A (es) | Composicion farmaceutica. | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| MX2020011504A (es) | Composicion farmaceutica que comprende salbutamol. | |
| WO2018085495A3 (en) | Dissolvable films and methods of their use | |
| PH12021550439A1 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| WO2019098572A3 (ko) | 간염 바이러스에 의해 유발된 간 섬유화의 개선을 위한 약학 조성물 | |
| WO2021111311A3 (ko) | 국소 부착 키나아제 저해제로서 신규한 아다만탄 유도체 | |
| EA202192475A1 (ru) | Способ получения стабильных пептидных составов | |
| EP3898596A4 (en) | PHARMACEUTICAL COMPOUND, METHOD FOR MAKING IT AND ITS USE AS A THERAPEUTIC AGENT | |
| MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
| WO2018096525A3 (en) | Heteroaryl compounds and uses thereof | |
| MX2019000977A (es) | Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación. | |
| EA201990506A1 (ru) | Фармацевтическая композиция | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. |